LE
LEGN.US Legend Biotech Corp
- Market cap
- USD 3.39B
- P/E
- -
- P/B
- 2.67x
- ROE
- 3.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is LEGN.US undervalued?
Graham numberThe Graham number of Legend Biotech Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Legend Biotech Corp fundamental analysis
No fundamental analysis for Legend Biotech Corp yet.
Legend Biotech Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Legend Biotech Corp
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous …
Full company profileLegend Biotech Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Legend Biotech Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 23.6M | 49.1M | 61.8M | 75.0M | 68.8M | 117M | 285M | 627M | 1.03B | 1.40B |
| Gross Profit | 23.7M | 49.1M | 61.8M | 75.0M | 68.8M | 51.6M | 141M | 393M | 621M | 788M |
| Operating Income | 13.8M | -1.53M | -133M | -313M | -392M | -456M | -439M | -303M | -137M | 72.9M |
| EBITDA | 14.1M | 149K | -127M | -298M | -392M | -417M | -478M | -113M | -232M | 136M |
| Net Income | 9.37M | -2.78M | -102M | -266M | -404M | -446M | -518M | -177M | -297M | 40.8M |
| EPS | 0.07 | -0.03 | -0.77 | -2.25 | -2.87 | -2.81 | -2.94 | -0.97 | -1.61 | 0.21 |
| Balance Sheet | ||||||||||
| Total Assets | 239M | 429M | 288M | 722M | 1.12B | 1.33B | 1.85B | 1.67B | 1.73B | 1.68B |
| Total Liabilities | 227M | 420M | 411M | 122M | 354M | 587M | 597M | 630M | 732M | 409M |
| Shareholders' Equity | 12.2M | 8.65M | -123M | 598M | 766M | 744M | 1.25B | 1.04B | 1.00B | 1.27B |
| Cash & Short-term Investments | 2.12M | 216M | 159M | 506M | 882M | 1.03B | 1.31B | 1.12B | 949M | 853M |
| Total Debt | 269K | 4.32M | 6.11M | 3.70M | 123M | 285M | 329M | 351M | 414M | 167M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -2.38M | 308M | -83.1M | -223M | -198M | -201M | -393M | -144M | -100M | -190M |
| Capital Expenditure | 887K | 21.0M | 39.2M | 30.3M | 45.4M | 22.3M | 22.7M | 14.1M | 67.6M | 69.6M |
| Free Cash Flow | -3.26M | 287M | -122M | -253M | -244M | -224M | -416M | -158M | -168M | -259M |
| Ratios | ||||||||||
| ROE | 77.0% | -32.2% | - | -44.6% | -52.7% | -60.0% | -41.4% | -17.0% | -29.6% | 3.2% |
| ROA | 3.9% | -0.6% | -35.3% | -36.9% | -36.1% | -33.5% | -28.0% | -10.6% | -17.1% | 2.4% |
| Net Profit Margin | 39.7% | -5.7% | -164.4% | -355.2% | -586.4% | -381.5% | -181.8% | -28.2% | -28.8% | 2.9% |
| Debt to Equity | 0.02x | 0.50x | - | 0.01x | 0.16x | 0.38x | 0.26x | 0.34x | 0.41x | 0.13x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Legend Biotech Corp dividends
Legend Biotech Corp has not paid dividends in the last 9 fiscal years.
Who owns Legend Biotech Corp
- Insiders 2.09%
- Institutions 51.59%
- Public & others 46.32%
- Shares outstanding 194M
- Free float 91.0M
Top funds holding LEGN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Select Pharmaceuticals Port | 2.59M | 1.34% | 0.00% | Sep 2026 |
| Strategic Advisers Fidelity US TtlStk | 2.53M | 1.30% | +7.88% | Sep 2026 |
| Fidelity Select Health Care | 2.28M | 1.18% | +11.84% | Aug 2026 |
| Fidelity Contrafund | 1.92M | 0.99% | +27.31% | Sep 2026 |
| Fidelity VIP Contrafund Initial | 1.89M | 0.97% | 0.00% | Sep 2026 |
| Fidelity Emerging Markets | 1.73M | 0.89% | 0.00% | Sep 2026 |
| Fidelity OTC | 1.48M | 0.76% | -60.03% | Aug 2026 |
| Harbor Small Cap Growth Instl | 1.45M | 0.75% | +35.51% | Sep 2026 |
| iShares Biotechnology ETF | 1.28M | 0.66% | -0.19% | Oct 2026 |
| Fidelity Advisor Health Care I | 1.08M | 0.56% | 0.00% | Sep 2026 |
| iShares Core MSCI Emerging Markets ETF | 835K | 0.43% | 0.00% | Oct 2026 |
| Fidelity Puritan | 816K | 0.42% | -45.18% | Jul 2026 |
| Belfius Equities Cure C Cap | 787K | 0.41% | +67.42% | Apr 2026 |
| HBM Healthcare Investments AG Ord | 721K | 0.37% | 0.00% | Sep 2026 |
| Fidelity China Region | 653K | 0.34% | 0.00% | Sep 2026 |
| Strategic Advisers Fidelity Em Mkts | 639K | 0.33% | 0.00% | Sep 2026 |
| JPM Global Healthcare C acc USD | 553K | 0.29% | -1.03% | Sep 2026 |
| Invesco Biotechnology & Genome ETF | 545K | 0.28% | 0.00% | Oct 2026 |
| Jupiter Merian Glb Eq Abs Rt I USD Acc | 537K | 0.28% | -22.03% | Jun 2026 |
| Fidelity Blue Chip Growth | 484K | 0.25% | 0.00% | Sep 2026 |
Top institutions holding LEGN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 29.1M | 15.00% | +13.22% | Jun 2026 |
| Deerfield Management Co | 8.14M | 4.20% | +5.85% | Jun 2026 |
| Suvretta Capital Management, LLC | 7.07M | 3.64% | -6.74% | Jun 2026 |
| Hillhouse Capital Advisors, Ltd. | 5.98M | 3.09% | 0.00% | Jun 2026 |
| Westfield Capital Management Company, L.P. | 5.15M | 2.66% | +16.25% | Sep 2026 |
| BlackRock Inc | 4.73M | 2.44% | +0.90% | Jun 2026 |
| Assenagon Asset Management SA | 3.83M | 1.97% | 0.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 3.66M | 1.89% | +150.14% | Jun 2026 |
| Point72 Asset Management, L.P. | 3.08M | 1.59% | -20.84% | Jun 2026 |
| Kynam Capital Management, LP | 3.00M | 1.55% | +90.40% | Jun 2026 |
| Artisan Partners Limited Partnership | 1.56M | 0.80% | -30.83% | Jun 2026 |
| State Street Corp | 1.50M | 0.77% | +0.02% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.39M | 0.72% | +131.17% | Jun 2026 |
| Renaissance Technologies Corp | 1.23M | 0.63% | +22.71% | Sep 2026 |
| Soleus Capital Management, L.P. | 1.21M | 0.62% | 0.00% | Jun 2026 |
| Driehaus Capital Management LLC | 1.16M | 0.60% | 0.00% | Jun 2026 |
| Ghisallo Capital Management LLC | 1.00M | 0.52% | 0.00% | Jun 2026 |
| Matthews International Capital Management, LLC | 917K | 0.47% | -0.93% | Jun 2026 |
| Davern Capital Partners, L.P. | 829K | 0.43% | -30.44% | Sep 2026 |
| Johnson & Johnson | 815K | 0.42% | 0.00% | Jun 2026 |
Legend Biotech Corp company profile
- Company name
- Legend Biotech Corp
- Ticker
- LEGN.US
- Exchange
- USA Stocks
- Listed since
- Jun 5, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3,300
- Fiscal year end
- December
- Address
- 2101 Cottontail Lane, Somerset, NJ, United States, 08873
- Phone
- 737 317 5050
- Website
- legendbiotech.com
About Legend Biotech Corp
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Legend Biotech Corp management
10- Ms. Ingrid ZhangChief Executive Officer · born 1973
- Mr. Carlos Santos GarciaChief Financial Officer · born 1972
- Ms. Ananda Elizabeth Martin Esq., J.D.Global Compliance Officer & Head of Government Affairs · born 1973
- Mr. Robert StaloffGeneral Counsel
- Dr. Yuhong Qiu Ph.D.Interim Head of Research & Development and Senior VP of Regulatory Affairs
- Mr. Birk VanderweeenSenior Vice President of Global Manufacturing & Supply
- Dr. Tracy Luo M.D.Senior VP of Enterprise Strategy & PMO and China General Manager
- Mr. Alan S. BashPresident of CARVYKTI Business Unit · born 1972
- Dr. Josh Schwartz M.D.Senior Vice President of Medical Affairs
- Mr. Byoung Ryu Ph.D.Senior Vice President of U.S./Ireland Research